Table 1.
Patients clinical characteristics
| Patients parameters | n = 50 | TCMR | No-TCMR | P value |
|---|---|---|---|---|
| Mean age (SD), years | 51 (15) | 45 (13) | 52 (15) | 0.25 |
| Gender, male (%) | 28 (56) | 2 (28) | 26 (60) | NS |
| Race (%) | ||||
| White | 17 (34) | 3 (43) | 14 (33) | NS |
| Black | 21 (42) | 1 (14) | 20 (46) | NS |
| Asian | 7 (14) | 3 (43) | 4 (9) | NS |
| Others | 5 (10) | 0 | 5 (12) | NS |
| Preemptive (%) | 8 (16) | 1 (14) | 7 (16) | NS |
| Mean CIT (SD) hours | 19.7 (12.9) | 12.5 (16.8) | 20 (12.3) | 0.22 |
| Cause of kidney disease (%) | ||||
| HTN | 8 (16) | 1 (14) | 7 (16) | NS |
| DM and HTN | 16 (32) | 2 (29) | 14 (32) | NS |
| Glomerular diseases | 17 (34) | 3 (43) | 14 (32) | NS |
| Others | 10 (20) | 1 (14) | 9 (20) | NS |
| DGF | 18 (36) | 1 (14) | 17 (39) | NS |
| Induction therapy (%) | ||||
| Thymoglobulin | 36 (72) | 4 (57) | 32 (74.4) | NS |
| Alemtuzumab | 7(14) | 0 | 7 (16.2) | NS |
| Basiliximab | 7 (14) | 3 (43) | 4 (9.3) | NS |
| Type of Donor (%) | ||||
| Living | 16 (32) | 4 (57) | 12 (28) | NS |
| Deceased | 34 (68) | 3 (43) | 31 (72) | NS |
TCMR T cell mediated rejection, SD standard deviation, NS not significant, CIT cold ischemic time, DM diabetes mellitus, HTN hypertension, DGF delayed graft function